Search results
Where Will Madrigal Pharmaceuticals Be in 3 Years?
Motley Fool via Yahoo Finance· 2 hours agoMadrigal Pharmaceuticals (NASDAQ: MDGL) is in a position that most other biotechs envy. Its first medicine just hit the market, sales are due to start...
These 3 Clinical-Stage Biotech Stocks Can Offer Exponential Gains | Investing.com NG
Investing.com· 21 hours agoShares Analysis by The Tokenist (Timothy Fries) covering: Pfizer Inc, Ocuphire Pharma Inc, Rocket ...
3 Growth Stocks You Can Buy Right Now Without Any Hesitation
Motley Fool via Yahoo Finance· 5 hours agoThree Motley Fool contributors believe they've identified good picks -- and they're all big biotech...
7 A-Rated Biotech Stocks Worth Betting On in June
InvestorPlace· 1 day agoLet me be clear: investing in biotech stocks isn’t for everyone. Investing in smaller biotech companies requires research, patience, and risk tolerance.
Better Biotech Stock: Viking Therapeutics vs. Madrigal Pharmaceuticals
Motley Fool via Yahoo Finance· 5 days agoViking Therapeutics (NASDAQ: VKTX) and Madrigal Pharmaceuticals (NASDAQ: MDGL) are highly prominent ...
Big Pharma Has the Firepower for Biotech Deal-Making
ETF Trends· 1 day agoIn the early innings of 2024, there was a flurry of consolidation in the biotech industry. It stoked hopes that this would finally be the year in which...
Radiopharma biotech Telix drops $200M Nasdaq IPO plans at last minute
FierceBiotech· 1 day agoInvestors celebrating the summer resurgence of biotech IPOs might want to put the champagne back on...
Cancer-fighting biotech startup InduPro raises $85M round - Puget Sound Business Journal
The Business Journals· 20 hours agoInduPro Inc., a biotech company dual-headquartered in Seattle and Cambridge, Massachusetts, has...
Madrigal Pharmaceuticals Stock Earns RS Rating Upgrade
Investor's Business Daily· 3 days agoOn Wednesday, Madrigal Pharmaceuticals stock earned an upgrade to its Relative Strength (RS) Rating,...
An Intrinsic Calculation For Duopharma Biotech Berhad (KLSE:DPHARMA) Suggests It's 22% Undervalued
Simply Wall St. via Yahoo Finance· 2 days agoSWOT Analysis for Duopharma Biotech Berhad Strength Debt is well covered by earnings. Dividends are...